- Trials with a EudraCT protocol (44,399)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,399 result(s) found.
Displaying page 2,019 of 2,220.
| EudraCT Number: 2004-001928-20 | Sponsor Protocol Number: ub004 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:UCB Pharma Belgium | |||||||||||||
| Full Title: Open-label, multi-centre study to compare the effectiveness of QvarTM Autohaler therapy with conventional therapy (similar doses) in children with stable asthma | |||||||||||||
| Medical condition: Children aged 7 - 12 with stable mild persistent to moderate persistent asthma (according to the GINA classification) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-021755-34 | Sponsor Protocol Number: 2010-021755-34 | Start Date*: 2010-07-22 | |||||||||||||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||||||||||||
| Full Title: Phase II study on imatinib in combination with RAD001 in advanced chordoma | |||||||||||||||||||||||
| Medical condition: PDGFRB and mTOR (or S6 or 4BP1) positive advanced chordoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2016-002270-12 | Sponsor Protocol Number: TRIMETA | Start Date*: 2016-10-20 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA | |||||||||||||
| Full Title: Clinical trial phase II, prospective, open, randomized, controlled study to evaluate the preventive effect of trimetazidine on the cardiotoxicity of trastuzumab and chemotherapy in patients with br... | |||||||||||||
| Medical condition: BREAST CANCER | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004129-22 | Sponsor Protocol Number: CJDQ443A12101 | Start Date*: 2021-02-22 |
| Sponsor Name:Novartis Pharma AG | ||
| Full Title: A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation | ||
| Medical condition: advanced solid tumors harboring the KRAS G12C mutation | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-003370-35 | Sponsor Protocol Number: MCT8-2019-2 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Rare Thyroid Therapeutics International AB | ||
| Full Title: Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II | ||
| Medical condition: Monocarboxylate Transporter 8 (MCT8) deficiency | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | |
| Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Trial now transitioned) NL (Trial now transitioned) IT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-000417-37 | Sponsor Protocol Number: ARRAY-818-202 | Start Date*: 2019-07-16 | |||||||||||
| Sponsor Name:Array BioPharma Inc. | |||||||||||||
| Full Title: A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer | |||||||||||||
| Medical condition: BRAF V600E-mutant Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-020305-32 | Sponsor Protocol Number: CRAD001CIT27T | Start Date*: 2010-08-06 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
| Full Title: A phase II, open label study to evaluate the activity and safety of Everolimus in association to Imatinib in PDGFRA-D842V unresectable or metastatic gastrointestinal stromal tumours (GISTs)as... | |||||||||||||
| Medical condition: patients with unresectable and/or metastatic gastrointestinal stromal tumours with exon 18 PDGFRA mutation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-017798-39 | Sponsor Protocol Number: PROVAX study | Start Date*: 2010-07-08 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
| Full Title: An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study) | |||||||||||||
| Medical condition: Prostate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated level... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000555-10 | Sponsor Protocol Number: HO147 | Start Date*: 2018-06-21 | |||||||||||
| Sponsor Name:HOVON Foundation | |||||||||||||
| Full Title: Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study. | |||||||||||||
| Medical condition: Smoldering multiple myeloma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) NO (Trial now transitioned) CZ (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-003366-27 | Sponsor Protocol Number: R-SRNS17 | Start Date*: 2017-12-21 |
| Sponsor Name:Radboud University Nijmegen Medical Center | ||
| Full Title: Efficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome unresponsive to 8 weeks of high dose prednisone. | ||
| Medical condition: Idiopathic nephrotic syndrome Focal segmental glomerulosclerosis Minimal change disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-004493-26 | Sponsor Protocol Number: D9670C00001 | Start Date*: 2020-09-02 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) versus Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose... | |||||||||||||
| Medical condition: HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) PT (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-002202-18 | Sponsor Protocol Number: INT 07/07 | Start Date*: 2008-01-11 | ||||||||||||||||||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | ||||||||||||||||||||||||||||
| Full Title: CALENDULA POMADE VERSUS PLACEBO CREAM/CORTISONE CREAM (FLUORCORTOLONE) IN THE PREVENTION OF CUTANEOUS ERYTHEMA DUE TO BREAST IRRADIATION. A RANDOMIZED STUDY ON 60 PATIENTS | ||||||||||||||||||||||||||||
| Medical condition: Patients treated for the first time with radiotherapy to the residual breast after quadrantectomy for proven non-metastatic breast cancer. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2021-000042-17 | Sponsor Protocol Number: M21SAD | Start Date*: 2021-12-29 | |||||||||||||||||||||||||||||||
| Sponsor Name:Netherlands Cancer Institute | |||||||||||||||||||||||||||||||||
| Full Title: Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study – SADDRIN-1 | |||||||||||||||||||||||||||||||||
| Medical condition: soft tissue sarcomas | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-005741-17 | Sponsor Protocol Number: 76096 | Start Date*: 2021-08-25 |
| Sponsor Name:Amsterdam University Medical Centers, location AMC | ||
| Full Title: Hyperbaric OXygen therapy for ACute Acoustic Trauma | ||
| Medical condition: Acute acoustic trauma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-001062-93 | Sponsor Protocol Number: CRC-01 | Start Date*: 2008-09-04 |
| Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | ||
| Full Title: Perioperative treatment with COI-E (capecitabine, oxaliplatin, irinotecan and cetuximab) of liver metastasis of colorectal carcinoma potentially resectable although at high risk of recurrences | ||
| Medical condition: Patients affected by colorectal metastases to the liver only (stage IV-liver only) defined as potentially resectable although at high risk of recurrence according to INT-MILAN internal guidelines. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-009418-42 | Sponsor Protocol Number: INT-07/09 | Start Date*: 2009-05-19 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
| Full Title: Phase II study evaluating efficacy and tolerability of Sorafenib in the treatment of iatrogenic lymphedema occurring in breast cancer patients following surgical dissection of, and/or radiotherapy ... | |||||||||||||
| Medical condition: Breast cancer patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-005742-14 | Sponsor Protocol Number: GS-US-592-6173 | Start Date*: 2022-08-02 | |||||||||||
| Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
| Full Title: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced I... | |||||||||||||
| Medical condition: Programmed cell death ligand 1 (PD-L1) positive metastatic triple-negative breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-001239-95 | Sponsor Protocol Number: TCD17620 | Start Date*: 2023-04-25 | |||||||||||
| Sponsor Name:Sanofi Aventis Recherche & Développement | |||||||||||||
| Full Title: A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as m... | |||||||||||||
| Medical condition: Cancer, solid tumor | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) NL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-003676-38 | Sponsor Protocol Number: INT-OM2-001 | Start Date*: 2005-09-13 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
| Full Title: CAPECITABINE TIME TABLE AND RADIOTHERAPY AS ADJUVANT THERAPY IN RECTAL CANCER | |||||||||||||
| Medical condition: This trial evaluates safety diarrhea, proctitis and cistitis of Grade 3/4 of radiochemotherapy with time table Capecitabine as adjuvant treatment in rectal cancer after radical surgery. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-002480-30 | Sponsor Protocol Number: - | Start Date*: 2023-07-18 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | |||||||||||||
| Full Title: PeRinatal Outcomes with ACTive versus expectant management of women with Pre-labor Rupture Of Membranes: a phase III, open-label, randomized controlled multicentric trial | |||||||||||||
| Medical condition: 1400 Women with PROM at term and a GBS negative swab | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.